{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T02:44:07Z","timestamp":1786157047954,"version":"build-2736575974"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018776","name":"UF Health Cancer Center","doi-asserted-by":"publisher","award":["P30CA247796"],"award-info":[{"award-number":["P30CA247796"]}],"id":[{"id":"10.13039\/100018776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While neoadjuvant FOLFIRINOX is an effective regimen for pancreatic ductal adenocarcinoma (PDAC), toxicity frequently limits its use. Nanoliposomal irinotecan (nal-IRI) offers improved pharmacokinetic properties and may mitigate some of the side effects. We conducted a multi-institutional, phase II study to evaluate the safety and clinical activity of neoadjuvant NALIRIFOX (nal-IRI, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with resectable and borderline resectable (R\/BR) PDAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with untreated R\/BR PDAC received 8 cycles of neoadjuvant NALIRIFOX. The primary endpoint was the 30-day post-operative major complication rate among resected patients. Secondary endpoints included treatment completion rate, R0 resection rate, objective response rate (ORR), biochemical (CA19-9) and radiographic responses, nodal downstaging, and quality of life (QoL by FACT-G).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 45 enrolled patients, 73% completed all 8 cycles of neoadjuvant NALIRIFOX. 34 patients (76%) underwent attempted surgery, of whom 29 (64%) had complete resection (15 BR patients and 14 R patients). The 30-day post-operative major complication rate was 10% (95% CI, 2.2-27%, P\u2009=\u2009.012), meeting the pre-specified threshold. R0 resection was achieved in 90% of resected patients. The radiographic ORR was 45% (95% CI, 29-62%), and the clinical benefit rate was 73% (95% CI, 58-85%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Neoadjuvant NALIRIFOX is a safe and active regimen in R\/BR PDAC with a low post-operative complication rate, high treatment completion and R0 resection rates, and meaningful clinical responses. These findings support further investigation of NALIRIFOX as part of a total neoadjuvant therapy approach in PDAC. [ClinicalTrials.gov identifier: NCT03483038].<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag250","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:05:48Z","timestamp":1782857148000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6249-9180","authenticated-orcid":false,"given":"Thomas J","family":"George","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Florida , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4495-8865","authenticated-orcid":false,"given":"Tuo","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and UF Health Cancer Institute , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9845-1074","authenticated-orcid":false,"given":"Ibrahim","family":"Nassour","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Florida , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4886-3169","authenticated-orcid":false,"given":"Sherise C","family":"Rogers","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Florida , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2783-8914","authenticated-orcid":false,"given":"Tim","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Florida , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2070-9319","authenticated-orcid":false,"given":"Ilyas","family":"Sahin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Florida , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4051-4551","authenticated-orcid":false,"given":"Brian H","family":"Ramnaraign","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Florida , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-1783","authenticated-orcid":false,"given":"Jesus","family":"Fabregas","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Florida , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0445-9452","authenticated-orcid":false,"given":"Kathryn","family":"Hitchcock","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Florida , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0368-4255","authenticated-orcid":false,"given":"Gonghao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and UF Health Cancer Institute , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen B","family":"Russell","sequence":"additional","affiliation":[{"name":"Tallahassee Memorial Hospital , Tallahassee, FL 32308,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4159-5376","authenticated-orcid":false,"given":"Anita A","family":"Turk","sequence":"additional","affiliation":[{"name":"Indiana University Simon Comprehensive Cancer Center Department of Medicine, , Indianapolis, IN 46202,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Kayaleh","sequence":"additional","affiliation":[{"name":"Orlando Health Cancer Institute , Orlando, FL 32806,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1812-8016","authenticated-orcid":false,"given":"Z Hugh","family":"Fan","sequence":"additional","affiliation":[{"name":"College of Engineering, University of Florida Department of Mechanical and Aerospace Engineering, , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2207-9552","authenticated-orcid":false,"given":"David L","family":"DeRemer","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Florida Department of Pharmacotherapy and Translational Research, , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9251-5543","authenticated-orcid":false,"given":"Ryan M","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Florida , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-5150","authenticated-orcid":false,"given":"Ji-Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and UF Health Cancer Institute , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J","family":"Hughes","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Florida , Gainesville, FL 32610,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"2026080722164821200_oyag250-B1","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ijrobp.2018.08.055","article-title":"Preoperative chemoradiotherapy potentially improves outcome for (borderline) resectable pancreatic cancer: preliminary results of the Dutch randomized phase III PREOPANC trial","volume":"102","author":"van Tienhoven","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080722164821200_oyag250-B2","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3389\/fonc.2019.01085","article-title":"Neoadjuvant therapy for resectable pancreatic cancer: an evolving paradigm shift","volume":"9","author":"Chawla","year":"2019","journal-title":"Front Oncol"},{"key":"2026080722164821200_oyag250-B3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13304-021-01186-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"74","author":"Gugenheim","year":"2022","journal-title":"Updates Surg"},{"key":"2026080722164821200_oyag250-B4","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cam4.444","article-title":"Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer","volume":"4","author":"Desai","year":"2015","journal-title":"Cancer Med"},{"key":"2026080722164821200_oyag250-B5","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1245\/s10434-016-5373-2","article-title":"Systematic review of resection rates and clinical outcomes after FOLFIRINOX-Based treatment in patients with locally advanced pancreatic cancer","volume":"23","author":"Rombouts","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2026080722164821200_oyag250-B6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1245\/s10434-014-4225-1","article-title":"Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas","volume":"22","author":"Blazer","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"2026080722164821200_oyag250-B7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jso.24375","article-title":"Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: is radiation necessary in the modern era of chemotherapy?","volume":"114","author":"Kim","year":"2016","journal-title":"J Surg Oncol"},{"key":"2026080722164821200_oyag250-B8","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2217\/fon-2023-0256","article-title":"A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma","volume":"19","author":"Singhal","year":"2023","journal-title":"Future Oncol"},{"key":"2026080722164821200_oyag250-B9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamaoncol.2021.5278","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial","volume":"10","author":"Sohal","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026080722164821200_oyag250-B10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","article-title":"Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial [published correction appears in JAMA Oncol. 2024 Apr 1; 10(4):541.]","volume":"7","author":"Sohal","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026080722164821200_oyag250-B11","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"key":"2026080722164821200_oyag250-B12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026080722164821200_oyag250-B13","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080722164821200_oyag250-B14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"2026080722164821200_oyag250-B15","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2018.36.15_suppl.4111","article-title":"A phase 1\/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil\/leucovorin (5-FU\/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC)","volume":"36","author":"Dean","year":"2018","journal-title":"JCO"},{"key":"2026080722164821200_oyag250-B16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026080722164821200_oyag250-B17","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"2026080722164821200_oyag250-B18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djz073","article-title":"Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"111","author":"Janssen","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2026080722164821200_oyag250-B19","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026080722164821200_oyag250-B20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2407-12-199","article-title":"A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma","volume":"12","author":"Hosein","year":"2012","journal-title":"BMC Cancer"},{"key":"2026080722164821200_oyag250-B21","article-title":"Neoadjuvant FOLF(IRIN)OX chemotherapy for resectable pancreatic adenocarcinoma: a multicenter randomized noncomparative phase II trial (PANACHE01 FRENCH08 PRODIGE48 study)","volume":"4","author":"Schwarz","year":"2025","journal-title":"J Clin Oncol."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag250\/68645788\/oyag250.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag250\/68645788\/oyag250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag250\/68645788\/oyag250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T02:16:54Z","timestamp":1786155414000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag250\/8721587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag250","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,6,29]]},"article-number":"oyag250"}}